tirzepatide bijwerkingen Medicatie voor obesitas: vooruitgang en uitdagingen | Nederlands Tijdschrift voor Diabetologie Weer een nieuw afslankmedicijn: vijf

You implement the least invasive strategies first and escalate only as needed

Mol Cells 17(1):23 Kastner T, Rivas MJI, Koch W, Nonhebel S (2012) Global changes in diets and the consequences for land requirements for food

The SELECT trial (2023) further demonstrated a 20% reduction in major adverse cardiovascular events, adding a cardioprotective dimension

The FDA has approved Foundayo (orforglipron), making it the second oral GLP-1 medication specifically approved for weight loss

Hanmi Pharmaceutical to launch by end of 2026 if the domestic Phase 3 trial succeeds Hanmi Pharmaceutical plans to conduct a phase 3 clinical trial to assess the efficacy and safety of 'HM11260C (efpeglenatide) in 420 obese adults without diabetes